Guide · Comparison
Estroven vs Amberen vs Relizen vs Remifemin: an evidence-based comparison
Side-by-side comparison of Estroven Complete, Amberen, Relizen and Remifemin: active ingredient, dose, trials, price per day, ratings, certification and flags.
Last updated · By the Solynes editorial team · Methodology
Short answer: Remifemin Menopause Relief uses the most-studied extract (iCR black cohosh) and is the cheapest of the four at $0.50/day, so it scores highest here (61.8/100). Estroven Complete uses ERr 731 rhubarb extract at the trial dose but has no trial of its own. Amberen and Relizen have small trials of their own (Amberen's are maker-linked; Relizen's study does not state its funding). None is NSF-listed, and The Menopause Society (2023) recommends none of these ingredients for hot flashes.
Side-by-side comparison
| Estroven Complete Multi-Symptom Menopause Relief | Amberen Multi-Symptom Menopause Relief | Bonafide Relizen | Remifemin Menopause Relief | |
|---|---|---|---|---|
| Our score | 55.0/100 (#8) | 50.9/100 (#11) | 48.2/100 (#18) | 61.8/100 (#5) |
| Active per day | Rhapontic rhubarb root extract ERr 731 4 mg | Ammonium succinate blend (Amber-M Complex) 400 mg | Swedish flower pollen extract (PI-82 + GC-FEM) 320 mg | Black cohosh extract (iCR) 40 mg |
| Ingredient evidence | C ERr 731 rhapontic rhubarb | C Ammonium succinate (Amberen) | C Flower pollen extract | C Black cohosh |
| Trials of this product | None found for this product (ingredient trials only) | Radzinskii 2016, Radzinsky 2019, Kachko 2024All manufacturer-linked; NAMS not recommended. | Bounous 2024General-population evidence relies on related Femal RCT (Winther 2005) and observational studies; controlled pooled data non-significant. | Osmers 2005, Bai 2007Best-studied black cohosh extract; but independent pooled evidence (Cochrane) and NAMS negative. |
| Menopause Society 2023 | Not recommended (Level II) – placebo-arm retention only 12.7% in key RCT; open-label study. | Not recommended (Level II) – limited, manufacturer-sponsored. | Not recommended (Level III). | Not recommended (Level I) – 'insufficient evidence to support use for VMS'. |
| Cost per day | $0.71 | $0.83 | $1.93 | $0.50 |
| Regular price | $19.99 / 28 days | $24.97 / 30 days | $58.00 / 30 days | $29.99 / 60 days |
| Amazon rating | ★ 4.419,727 ratings · Nov 19, 2026 | ★ 4.224,068 ratings · Nov 19, 2026 | ★ 41,832 ratings · Nov 19, 2026 | ★ 4.34,345 ratings · Nov 19, 2026 |
| Certification | None verified | None verified | “3rd-party tested” claim | None verified |
| Company | i-Health (dsm-firmenich) | Alliance Pharmaceuticals | Bonafide / Pharmavite (Otsuka) | Schaper & Brümmer (Germany) |
| Flags | Class actionWatchdog complaint | FTC orderFTC noticeWatchdog complaintUndisclosed amounts | FTC noticeWatchdog complaintPrivacy lawsuit | Liver caution |
Remifemin Menopause Relief
Each tablet contains the isopropanolic black cohosh extract (iCR) used in the largest manufacturer trials, including Osmers 2005 (304 women, better than placebo on the Menopause Rating Scale) and Bai 2007 (similar to tibolone). Independent pooled evidence is negative (Cochrane 2012). Black cohosh carries rare liver-injury reports; see our black cohosh safety guide.
Estroven Complete Multi-Symptom Menopause Relief
One caplet gives 4 mg of ERr 731, the dose used in two placebo-controlled trials in perimenopausal women (Heger 2006, Kaszkin-Bettag 2009), both from one research group. We found no Estroven-specific trial. The brand is part of i-Health (dsm-firmenich); a TINA.org warning letter (2024) concerned its menopause marketing, and a 2026 class action concerns other Estroven products (Mood Boost and Stress Relief), not this one.
Amberen Multi-Symptom Menopause Relief
An undisclosed blend of ammonium succinate and other salts studied in two identical placebo-controlled trials (pooled 227 women, Radzinsky 2019), both manufacturer-linked. A 2016 FTC order (against the former marketer, Lunada Biomedical) bars unsubstantiated menopause-relief claims, and TINA.org filed a 2024 complaint about later marketing. One case report links Amberen to a coronary artery dissection; causality is unproven (Nesheiwat 2019).
Bonafide Relizen
A purified flower-pollen extract. The general-population evidence relies on a related product's small trial (Winther 2005, 64 women) plus a 39-woman study in breast-cancer survivors (Bounous 2024); pooled controlled data were not significant (Acquarulo 2024). It is also the most expensive of the four at $1.93/day.
Which should you choose?
If you want one of these four, compare by the evidence you trust most: Remifemin has the most trials (mostly maker-linked); Estroven Complete matches a trial dose of ERr 731 at a low price; Amberen's formula is undisclosed; Relizen has the thinnest controlled evidence for its price. Before any of them, talk to a clinician about options with stronger evidence. See all 27 ranked.
FAQ
Which is better, Estroven or Amberen?
In our ranking, Estroven Complete scores 55.0 and Amberen Multi-Symptom 50.9. Estroven uses 4 mg ERr 731 (the trial dose, no product trial); Amberen has its own maker-linked trials but an undisclosed blend and an FTC history.
Is Relizen better than Remifemin?
Remifemin's iCR black cohosh extract has more trials and costs $0.50/day versus $1.93 for Relizen. Relizen is non-hormonal pollen extract with very limited controlled data. Neither is recommended by The Menopause Society for hot flashes.
More guides
- Do menopause supplements work? What the trials actually showNov 19, 2026
- Black cohosh: what the studies show, liver safety and adulterationNov 19, 2026
- Menopause supplements with NSF certification, checked against the registryNov 19, 2026
- Menopause supplements for hot flashes, sleep and mood: what's been studied for eachNov 19, 2026
- Soy isoflavones and breast cancer: what's known (and what isn't)Nov 19, 2026
*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Solynes does not sell supplements; descriptions summarize published research and are not medical advice.